Skip to Content

'
Diane C. Bodurka, M.D., F.A.C.O.G., F.A.C.S.

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice Chair for Education,, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Bodurka was recruited to the M.D. Anderson faculty in 1996 after she completed the institution's Gynecologic Oncology fellowship.  She has distinguished herself as a national leader in the area of postgraduate medical education.  Dr. Bodurka has authored and co-authored more than 100 peer-reviewed articles, numerous book chapters and many invited articles.  She is frequently invited to lecture at national and international meetings, as well as at meetings and conferences for patients and their caregivers.

  
Dr. Bodurka is the Vice-Chair for Education in the Department of Gynecologic Oncology.  In addition to education, her research interests include quality of life issues, patient-reported outcomes, cost-effectiveness analysis and other types of Health Services Research.  She is the Principal Investigator for many quality of life and Health Services Research studies, as well as several clinical trials involving novel therapeutics in the treatment of ovarian cancer.  Dr. Bodurka is currently Co-Principal Investigator of the Department's T32 Grant entitled "Training of Academic Gynecologic Oncologists", one of only two NIH Training Grants held by Departments of Gynecologic Oncology.

Dr. Bodurka is an active member of many national organizations including the Society of Gynecologic Oncologists and the American Society of Clinical Oncology.  She serves on the council of the Society of Gynecologic Oncologists, is the Director of the Health Services Research Group, and is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee.  Dr. Bodurka has recently been elected to the American Gynecological and Obstetrical Society and The University of Texas Academy of Health Science Educators.  Her clinical excellence and commitment to patient care have been recognized by being named as one of the Best Doctors in America, Houston's Top Doctors, and America's Top Oncologists.

Office Address

The University of Texas MD Anderson Cancer Center
P.O. Box 301439
Unit Number: 1362
Houston, TX 77230-1439

Education & Training

Degree-Granting Education

1990 Georgetown University School of Medicine, Washington, D.C., MD, Medicine

Postgraduate Training

2004-2005 Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1994-6/1996 Fellowship, Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Mitchell Morris
7/1990-6/1994 Internship and Residency, Obstetrics and Gynecology, The University of Alabama, Birmingham, AL, Dr. Benjamin Younger

Board Certifications

2012 American Board of Obstetrics and Gynecology
1997 American Board of Obstetrics and Gynecology

Experience/Service

Academic Appointments

Voluntary Assistant Clinical Professor, The University of California, San Diego, School of Medicine, San Diego, CA, 2005-2010
Associate Professor, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003-2008
Assistant Professor (tenure track), Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-2003
Assistant Professor, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center (non-tenure track), Houston, TX, 1996-2000
Junior Faculty Associate, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1994-1996

Administrative Appointments/Responsibilities

Member, Executive Committee, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present
Director, Health Services Research Program, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010-present
Medical Director, Advanced Practice Nurse Midlevel Providers,, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2011
Rotation Coordinator, Step-Up Biomedical Engineering/Bioengineering Student Interns, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2010
Co-Director, Career Development Program for the Uterine SPORE, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-present
Director, Gynecologic Oncology Rotation for Hematology/Oncology Fellows, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006-2012
Chair, Fellowship Planning Committee, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2002-2012
Director, Fellowship Training Program, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001-2012
Co-Director, Ovarian Cancer Screening Clinic, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001-2005
Program Director, Resident Rotations, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-2012
Assistant Director, Fellowship Training Program, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-2001
Director, Ovarian Cancer Screening Clinic, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1996-2001

Other Appointments/Responsibilities

Member, Comparative Effectiveness Research Working Group, Gynecologic Oncology Group, Philadelphia, PA, 2010-2011
Member, Quality of Life Committee, Gynecologic Oncology Group, Philadelphia, PA, 1999-2009
Member, Data Management Committee, Gynecologic Oncology Group, Philadelphia, PA, 1998-2009

Consultantships

Oncology.com, Washington, 2000-present
Web.md, Washington, D.C., 2000-present

Institutional Committee Activities

Member, Trainee Excellence Awards Committee, 2010-present
Member, Patient Care Operations Team, Department of Gynecologic Oncology and Reproductive Medicine, 2009-2012
Member, Clinical Fellowship Awards Selection Committee, 2008-present
Chair, Distinguished Alumnus Award Subcommittee of the MD Anderson Alumni and Faculty Association, 2008-present
Member, Gynecology Center Survivorship Program Project, Department of Gynecologic Oncology and Reproductive Medicine, 2008-2011
Alternate Departmental Representative, Department of Gynecologic Oncology and Reproductive Medicine, Credentials Committee of the Medical Staff, 2008-2011
Member, Multidisciplinary Disposition Conference Redesign Group, Department of Gynecologic Oncology and Reproductive Medicine, 2008-2011
Member, Step-Up Advisory Board, 2008-2010
Member, Search Committee, Chair of Department of Surgical Oncology, 2008-2010
Member, Continuing Medical Education Advisory Committee, 2008-2010
Member, Academic Affairs & Medical Education Working Group, 2008-2010
Member, MD Anderson Cancer Center Alumni and Faculty Association Steering Committee, 2007-present
Member, Gynecologic Oncology Group Operations Committee, Department of Gynecologic Oncology and Reproductive Medicine, 2006-present
Member, Educational Resources Committee, 2006-present
Member, Executive Committee, Blanton-Davis Ovarian Cancer Research Program, 2006-2012
Member, Fellowship Steering Committee, Hematology/Oncology Fellowship Program, 2006-2012
Member, Faculty Achievement Awards Committee, 2006-2008
Member, Education Council, 2006-2007
Chair, Graduate Medical Education Committee, 2006-2007
Chair, Quality of Life, Health Services Research and Survivorship Working Group, Department of Gynecologic Oncology and Reproductive Medicine, 2004-2009
Vice-Chair, Graduate Medical Education Committee, 2003-2005
Vice-Chair Elect, Graduate Medical Education Committee, 2001-2003
Member, Ethel Fleming Arceneaux Award Selection Committee, 2001
Chair, Admissions Subcommittee, Department of Gynecologic Oncology and Reproductive Medicine, 2000-present
Member, Institutional Review Board, 2000-2003
Member, Psychosocial, Behavioral and Health Services Research Committee, 1999-2001
Member, Search Committee, Director of Human Clinical Cancer Genetics, 1999-2001
Member, Medical Practice Subcommittee of the Executive Committee, 1997-2005
Member, Faculty Senate, 1997-2001

Honors and Awards

2012 America's Top Obstetricians and Gynecologists
2011-2012 Best Doctors in America®
2011-2012 Castle Connolly's America's Top Doctors for Cancer
2011-2012 U. S. News Top Doctors
2011 America's Top Obstetricians and Gynecologists
2011 America's Top Oncologists
2011 International Who's Who of Professional & Business Women's Hall of Fame
2011 Marquis Who's Who In Medicine
2011 The William Randolph Hearst Foundations Faculty Achievement Award in Education, MD Anderson Cancer Center
2010-2011 Best Doctors in America®
2010-2011 Castle Connolly's America's Top Doctors for Cancer
2010 America's Top Obstetricians and Gynecologists
2010 America's Top Oncologists
2010 Association of Professors of Gynecology and Obstetrics Excellence in Teaching Award
2009-2010 Best Doctors in America®
2009-2010 Castle Connolly's America's Top Doctors for Cancer
2009 America's Top Obstetricians and Gynecologists
2009 International Who's Who of Professional & Business Women
2009 Marquis Who's Who in America
2009 America's Top Oncologists
2009 Distinguished Teaching Professor, Elected, The University of Texas Academy of Health Science Education
2009 Fellow, American Gynecological and Obstetrical Society, New York, NY, Elected
2008-2009 Best Doctors in America®
2008-2009 Castle Connolly's America's Top Doctors for Cancer
2008-2009 Houston's Top Doctors
2008 America's Top Obstetricians and Gynecologists
2008 Women of the Year in Medicine and Healthcare
2007-2008 Best Doctors in America®
2007 America's Top Obstetricians and Gynecologists
2007 Educator of the Month, February, The University of Texas MD Anderson Cancer Center
2006-2007 Best Doctors in America®
2005-2006 APGO/Solvay Education Scholar
2005-2006 Best Doctors in America®
2005 America's Top Obstetricians and Gynecologists
2004 America's Top Obstetricians and Gynecologists
2004 Educator of the Month, May, The University of Texas MD Anderson Cancer Center
2003 Outstanding Educator, The University of Texas MD Anderson Cancer Center
2000 ACOG/Wyeth-Ayerst Fellowship in Women's Health Policy
2000 Finalist, Julie and Ben Rogers Award for Excellence in Education, The University of Texas MD Anderson Cancer Center
1994 Administrative Chief Resident, The University of Alabama at Birmingham
1994 Alpha Omega Alpha, The University of Alabama at Birmingham
1994 Best Teaching Resident, The University of Alabama at Birmingham

Selected Publications

Peer-Reviewed Original Research Articles
1. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: The MD Anderson Cancer Center experience. Gynecol Oncol 117(3):467-72, 6/2010. e-Pub 3/2010. PMCID: PMC2882061.
2. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: Implications for Survivors. Cancer 116(3):625-630, 2/2010. e-Pub 1/2010. PMID: 20052724.
3. Tung CS, Sun CC, Schlumbrecht MP, Meyer LA, Bodurka DC. Survival after intestinal perforation: Can it be predicted? Gynecol Oncol 115(3):349-53, 12/2009. e-Pub 9/2009. PMID: 19765809.
4. Shinn EH, Taylor CL, Kilgore K, Valentine A, Bodurka DC, Kavanagh J, Sood A, Li Y, Basen-Engquist K. Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. Palliat Support Care 7(3):299-306, 9/2009. PMID: 19788771.
5. Torres MA, Jhingran A, Thames HD, Levenback CF, Bodurka DC, Ramondetta LM, Eifel PJ. Concurrent chemoradiation in the routine management of patients with cervical cancer: Does marital status matter? Int J Gynecol Cancer 19(6):1107-1112, 8/2009. PMID: 19820377.
6. Hoffman MS, Bodurka DC. Surgical education and training program development for gynecologic oncology: American perspective. Gynecol Oncol 114(2 Suppl):S47-51, 8/2009. PMID: 19573707.
7. Gershenson DM, Sun CC, Bodurka DC, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 7/2009. e-Pub 4/2009. PMID: 19361839.
8. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/2009. PMCID: PMC2680417.
9. Basen-Engquist K, Scruggs S, Jhingran A, Bodurka DC, Lu K, Ramondetta L, Hughes D, Carmack Taylor C. Physical activity and obesity in endometrial cancer survivors: Associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol 200(3):288.e1-e8, 3/2009. e-Pub 12/2008. PMCID: PMC2666540.
10. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR. Carcinoma of the lower uterine segment: A newly described association with Lynch Syndrome. J Clin Oncol 26(36):5965-71, 12/2008. e-Pub 11/2008. PMCID: PMC2645115.
11. Frumovitz M, Soliman PT, Greer M, Schmeler KM, Moroney J, Bodurka DC, Ramirez PT. Laparoscopy training in gynecologic oncology fellowship programs. Gynecol Oncol 111(2)(2):197-201, 11/2008. e-Pub 9/2008. PMID: 18804849.
12. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer 18(4):660-669, 7/2008. e-Pub 9/2007. PMID: 17892451.
13. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 110(1):65-70, 7/2008. e-Pub 5/2008. PMID: 18455781.
14. Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer 8:101, 4/2008. PMCID: PMC2362122.
15. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-4, 3/2008. e-Pub 12/2007. PMID: 18155273.
16. Torres MA, Jhingran A, Thames HD, Levenback CF, Bodurka DC, Ramondetta LM, Eifel PJ. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys 70(1)(1):118-25, 1/2008. e-Pub 9/2007. PMID: 17869451.
17. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105(3):625-9, 6/2007. e-Pub 2/2007. PMID: 17320156.
18. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol 104(1):100-3, 1/2007. e-Pub 9/2006. PMID: 16963111.
19. Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18-29, 1/2007. PMID: 17183353.
20. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, Lu KH, Bodurka DC. Are women ready for the HPV vaccine? Gynecol Oncol 103(1)(1):151-4, 10/2006. e-Pub 3/2006. PMID: 16551476.
21. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson DM. A phase II trial of oral capecitabine in patients with platinum-and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 102(3):468-74, 9/2006. e-Pub 3/2006. PMID: 16516276.
22. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 9/2006. PMID: 16946209.
23. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108(2):361-8, 8/2006. PMID: 16880307.
24. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: Prognostic differences between participants and nonparticipants. Cancer 106(11):2452-8, 6/2006. PMID: 16639738.
25. Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 101(1):55-61, 4/2006. e-Pub 11/2005. PMID: 16260029.
26. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101(1):126-31, 4/2006. e-Pub 11/2005. PMID: 16271384.
27. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98(3):172-80, 2/2006. PMID: 16449677.
28. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23(30):7703-20, 10/2005. e-Pub 9/2005. PMID: 16157938.
29. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428-36, 10/2005. PMID: 16234510.
30. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-27, 4/2005. e-Pub 11/2004. PMID: 15538640.
31. Frumovitz M, Slomovitz BM, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Endometrial Cancer: To stage or not to stage? J Amer Coll Surg 199:388-393, 12/2004.
32. Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, Bodurka DC. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 95(3):463-8, 12/2004. PMID: 15581947.
33. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 199(3):388-93, 9/2004. PMID: 15325608.
34. Frumovitz M, Ramirez PT, Greer M, Gregurich MA, Wolf J, Bodurka DC, Levenback C. Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. Gynecol Oncol 94(3):746-53, 9/2004. PMID: 15350368.
35. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, Levenback C, Gershenson DM. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 94(2):442-8, 8/2004. PMID: 15297186.
36. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 104(2):255-60, 8/2004. PMID: 15291996.
37. Smith JA, Kindo CC, Kurian S, Whitaker LM, Burke C, Wachel B, Sun CC, Weaver CL, Danielson MG, Fitzgerald MA, Munsell M, Zandstra FA, Bodurka DC. Evaluation of patient chemotherapy education in a gynecology oncology center. Support Care Cancer 12(8):577-83, 8/2004. e-Pub 5/2004. PMID: 15168104.
38. Ramondetta LM, Tortolero-Luna G, Bodurka DC, Sills D, Basen-Engquist K, Gano J, Levenback C. Approaches for end-of-life care in the field of gynecologic oncology: An exploratory study. Int J Gynecol Cancer 14(4):580-8, 7/2004. PMID: 15304150.
39. Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 22(5):881-9, 3/2004. PMID: 14990644.
40. Basen-Engquist K, Paskett ED, Buzaglo J, Miller SM, Schover L, Wenzel LB, Bodurka DC. Cervical cancer. Cancer 98(9 Suppl):2009-14, 11/2003. PMID: 14603537.
41. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21(2):291-7, 1/2003. PMID: 12525521.
42. Ramondetta LM, Bodurka DC, Tortolero-Luna G, Gordinier M, Wolf JK, Gershenson DM, Sciscione AC. Mentorship and productivity among gynecologic oncology fellows. J Cancer Educ 18(1):15-9, 2003. PMID: 12825629.
43. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: Do they change over time? Gynecol Oncol 87(1):118-28, 10/2002. PMID: 12468352.
44. Eifel PJ, Jhingran A, Bodurka DC, Levenback C, Thames H. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. J Clin Oncol 20(17):3651-7, 9/2002. PMID: 12202666.
45. Dalrymple JL, Levenback C, Wolf JK, Bodurka DC, Garcia M, Gershenson DM. Trends among gynecologic oncology inpatient deaths: Is end-of-life care improving? Gynecol Oncol 85(2):356-61, 5/2002. PMID: 11972400.
46. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99(1):3-10, 1/2002. PMID: 11777502.
47. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82(3):550-8, 9/2001. PMID: 11520154.
48. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, Webster K, Cella D, Hu S, Gershenson DM. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19(6):1809-17, 3/2001. PMID: 11251013.
49. Gordinier ME, Ramondetta LM, Parker LP, Wolf JK, Follen M, Gershenson DM, Bodurka-Bevers D. Survey of female gynecologic oncologists and fellows: Balancing professional and personal life. Gynecol Oncol 79(2):309-14, 11/2000. PMID: 11063663.
50. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, Gershenson DM. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 78(3 Pt 1):302-8, 9/2000. PMID: 10985884.
51. Bodurka-Bevers D, Morris M, Eifel PJ, Levenback C, Bevers MW, Lucas KR, Wharton JT. Posttherapy surveillance of women with cervical cancer: An outcomes analysis. Gynecol Oncol 78(2):187-93, 8/2000. PMID: 10926801.
52. Bodurka-Bevers D, Sun CC, Gershenson DM. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics 17:133-50, 2/2000. PMID: 10947337.

Invited Articles
1. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am 33(4):621-30, ix, 12/2006. PMID: 17116505.
2. Sun CC, Frumovitz M, Bodurka DC. Quality of life and gynecologic malignancies. Curr Oncol Rep 7(6):459-65, 11/2005. PMID: 16221383.
3. Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: Challenges and opportunities. Gynecol Oncol 97(3):916-23, 6/2005. PMID: 15907981.

Letters to the Editor
1. Slomovitz BM, Bodurka DC, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 105:218-9, 2005.

Manuals, Teaching Aids, Other Teaching Publications
1. Survivorship in Gynecologic Cancers, Gynecologic Cancer Foundation's State of the State Report, 9/2009.
2. Helping Cancer Patients with Quality of Life Treatment Decisions, American College of Obstetricians and Gynecologists ACOG Update, 2005.
3. Ovarian Cancer: Quality of Life Issues. National Ovarian Cancer Coalition, 2005.
4. New Diagnostic Tools on the Horizon: Supplement to The Washington Post sponsored by Gynecologic Cancer Foundation, 5/2002.
5. MD Anderson Gynecologic Oncology Handbook, 1996.
 

Other
1. Research Tool. The University of Texas MD Anderson Cancer Center, Preference Assessment Inventory (P.A.I.), U.S., copyright 2003.

Grant & Contract Support

Title: Training of Academic Gynecologic Oncologists
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/7/2011 - 6/30/2016
 
Title: Specialized Program of Research Excellence in Uterine Cancer Career Development Award
Funding Source: NIH/NCI
Role: Mentor
Principal Investigator: Karen Lu, M.D.,
Duration: 9/2007 - 8/2009
 
Title: WRHR Program
Funding Source: Baylor College of Medicine
Role: Mentor
Principal Investigator: Joe Leigh Simpson, M.D.
Duration: 2005 - 2010
 
Funding Source: MD Anderson Cancer Gynecologic SPORE for Uterine Cancer
Role: Co-Investigator
Principal Investigator: Thomas Burke, M.D.
Duration: 2003 - 2008
 
Title: Career Development Core
Funding Source: MD Anderson Cancer Gynecologic SPORE for Uterine Cancer
Role: Consultant
Principal Investigator: Thomas Burke, M.D.
Duration: 2003 - 2008
 
Title: Depression Screening and Treatment in Ovarian Cancer
Funding Source: NCI
Role: Co-Investigator
Principal Investigator: Eileen Shinn, Ph.D.
Duration: 2003 - 2008
 
Title: Sexual Functioning and Quality Of Life in Women with Cervical Cancer
Funding Source: NIH
Role: Principal Investigator
Duration: 2003 - 2006
 
Title: A Phase II Study of Irofulven (IND #48914) in Patients with Refractory or Recurrent Advanced Epithelial Ovarian Cancer Using Every-Other-Week Dosing
Funding Source: MGI Pharma
Role: Principal Investigator
Duration: 2002 - 2005
 
Title: Chemotherapy-Related Toxicities in Ovarian Cancer Patients: Preference Assessments of Patients
Funding Source: Blanton-Davis Ovarian Cancer Research Program Research Award
Role: Principal Investigator
Duration: 2002 - 2004
 
Title: The Elizabeth Registry for the Study of Low-Grade Ovarian Carcinoma
Funding Source: Private Philanthropic Funds, The Elizabeth Fund
Role: Principal Investigator
Duration: 2000 - 2010
 
Title: Modulation of Putative Surrogate End-point BioMarkers in Endometrial Biopsies from Women with HNPCC
Funding Source: NCI/DCP
Role: Co-Investigator
Principal Investigator: Dr. Karen Lu
Duration: 2000 - 2004
 
Title: Unrestricted Grant for Quality of Life and Patient Preferences Research
Funding Source: Merck and Company
Role: Investigator
Duration: 2000 - 2004
 
Title: Identifying Factors Associated with Early Detection of Ovarian Cancer
Funding Source: National Center for Chronic Disease Prevention & Health Promotion Centers for Disease Control and Prevention
Role: Co-Investigator
Principal Investigator: Dr. Guillermo Tortolero-Luna
Duration: 2000 - 2002
 
Title: Perceptions of Taxol-Carboplatin Toxicity and Quality of Life Among Ovarian Cancer Patients
Funding Source: Texas Federation of Business and Professional Women
Role: Principal Investigator
Duration: 2000 - 2002
 
Title: Study of Women at Increased Risk of Breast and Ovarian Cancer
Funding Source: The Ellwood Foundation
Role: Principal Investigator
Duration: 1999 - present
 
Title: Evaluating Patient Preferences Quality of Life and Symptoms of Treatment in Ovarian Cancer Patients Receiving High Dose and Standard Chemotherapy
Funding Source: PRS Institutional Research Grant
Role: Principal Investigator
Duration: 1999 - 2007
 
Title: Specialized Program of Research Excellence in Ovarian Cancer
Funding Source: NIH
Role: Collaborator
Principal Investigator: Dr. Robert Bast
Duration: 1999 - 2004
 
Title: The National Ovarian Cancer Early Detection Program
Funding Source: NCI
Role: Co-Investigator
Principal Investigator: Dr. David Fishman
Duration: 1999 - 2004
 
Title: Chemoprevention of Ovarian Cancer
Funding Source: U.S. Army (DOD)
Role: Investigator
Principal Investigator: Dr. David Gershenson
Duration: 1999 - 2000
 
Title: Prophylactic Mastectomy and Oophorectomy for Women at Risk of Breast and Ovarian Cancer: Incorporating Preferences in a Decision Analysis
Funding Source: PRS Institutional Research Grant
Role: Principal Investigator
Duration: 1998 - 2003

Last updated: 3/13/2013